A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
第1/2相
完了
NCT05975099
| 対象疾患 | Lyme Disease |
|---|
| 相 | 第1/2相 |
|---|
| スポンサー | ModernaTX, Inc. |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 807 名 |
|---|
| 介入（薬剤） | mRNA-1975, mRNA-1982 |
|---|
| 開始日 | 2023年7月26日 |
|---|
| 完了日 | 2025年5月30日 |
|---|
| 結果公開日 | 2026年7月30日 |
|---|
概要
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
Up to 7 days after Day 1 injection · Participants
| mRNA-1975 Dose Level 1 | 70 Participants |
|---|
| mRNA-1975 Dose Level 2 | 80 Participants |
|---|
| mRNA-1975 Dose Level 3 | 82 Participants |
|---|
| mRNA-1975 Dose Level 4 | 91 Participants |
|---|
| mRNA-1982 Dose Level 1 | 64 Participants |
|---|
| mRNA-1982 Dose Level 2 | 77 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection
Up to 7 days after Day 57 injection · Participants
| mRNA-1975 Dose Level 1 | 79 Participants |
|---|
| mRNA-1975 Dose Level 2 | 80 Participants |
|---|
| mRNA-1975 Dose Level 3 | 90 Participants |
|---|
| mRNA-1975 Dose Level 4 | 96 Participants |
|---|
| mRNA-1982 Dose Level 1 | 70 Participants |
|---|
| mRNA-1982 Dose Level 2 | 82 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection
Up to 7 days after Day 169 injection · Participants
| mRNA-1975 Dose Level 1 | 81 Participants |
|---|
| mRNA-1975 Dose Level 2 | 87 Participants |
|---|
| mRNA-1975 Dose Level 3 | 81 Participants |
|---|
| mRNA-1975 Dose Level 4 | 92 Participants |
|---|
| mRNA-1982 Dose Level 1 | 76 Participants |
|---|
| mRNA-1982 Dose Level 2 | 82 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。